Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 848-537-7 | CAS number: 1912392-88-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- sub-chronic toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1999
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 999
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 410 (Repeated Dose Dermal Toxicity: 21/28-Day Study)
- GLP compliance:
- no
- Remarks:
- method comparative to OECD TG 410
Test material
- Reference substance name:
- Tetramethylammonium hydroxide
- EC Number:
- 200-882-9
- EC Name:
- Tetramethylammonium hydroxide
- Cas Number:
- 75-59-2
- Molecular formula:
- C4H12N.HO
- IUPAC Name:
- tetramethylazanium hydroxide
Constituent 1
- Specific details on test material used for the study:
- TS: tetramethylammonium hydroxide 25%, Vehicle: water
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
Administration / exposure
- Type of coverage:
- not specified
- Vehicle:
- water
- Details on exposure:
- The vehicle (distilled water) and test substance formulation was applied to the reservoir of a Hill Top Chamber (Hill Top Biolabs, Inc., Cincinnati, Ohio) which was placed on the animal's shaven back behind the shoulder blades. The chamber was held secure with an elastic cloth band fastened with Velcro.
- Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- 6 h/day, 5 d/wk
Doses / concentrationsopen allclose all
- Dose / conc.:
- 2.5 mg/kg bw (total dose)
- Remarks:
- female
- Dose / conc.:
- 5.5 mg/kg bw (total dose)
- Remarks:
- male and female
- Dose / conc.:
- 10 mg/kg bw (total dose)
- Remarks:
- female
- Dose / conc.:
- 50 mg/kg bw (total dose)
- Remarks:
- female and male
- Dose / conc.:
- 120 mg/kg bw (total dose)
- Remarks:
- male
- Dose / conc.:
- 250 mg/kg bw (total dose)
- Remarks:
- male
- No. of animals per sex per dose:
- 10 males / 10 females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- The initial target dose levels were 0, 0.55, 5, 12 and 25% w/v. The dosages were administered 6 hours/day, 5 days/week, at a constant volume of 1 ml/kg bw. These dose levels were equivalent to 0, 5.5, 50, 120 and 250 mg/kg bw/day. On the first day of administration, all male rats in the 120 and 250 mg/kg bw groups died within 3 hours after dosing and one male in the 50 mg/kg group died at the end of the day. Therefore, the dose levels to be administered to the female rats were lowered and a total of 7 treatment groups (a vehicle control and 6 dose levels) were evaluated between both sexes.
Because of the early deaths, other design changes were implemented. In an attempt to determine a possible cause of test substance-induced toxicity/moribundity, blood samples were collected via the retroorbital plexus from five male and four female rats in the 5% dose level group for hematology and limited serum chemistry analysis on study Day 4 and 3, respectively. In addition, rats dying spontaneously within the first week of the study were subjected to a gross necropsy and any tissues with grossly observable lesions (excluding application site skin) were collected. After one week of treatment the rats that died (five in the 50 mg/kg dose group) were subjected to a complete necropsy and their tissues were preserved, regardless of gross appearance. At study termination (day29) all surviving rats were euthanized, a gross necropsy performed and all gross lesions were collected and preserved in 10% neutral buffered formalin for possible microscopic evaluation.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- All of the male rats in the 120 and 250 mg/kg bw dose groups died within 3 hours after treatment initiation. Clinical signs noted in a few of the rats in these groups were lethargy followed by convulsions, tremors, and death beginning within one and a half to 2 hours after administration of the first dose of the test substance. One female rat in the 50 mg/kg bw dose group exhibited hyperactivity and labored breathing. No overt clinical signs of toxicity were observed at the lower doses (males; 5.5 mg/kg bw: females; 2.5, 5.5 or 10 mg/kg bw).
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- Skin irritation at the application site included erythema, edema and/or scabbing in all groups treated with the test substance. In addition, scabbing (i.e.; possible grooming irritation) was seen in all groups, including the controls, and was considered to be associated with the animal's instinctive grooming behavior occurring when the collars were removed on the weekends.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- All of the male rats in the 120 and 250 mg/kg bw dose groups died within 3 hours after treatment initiation. The 50 mg/kg bw male and female rats died intermittently throughout the study with the longest survival being approximately 2 weeks. No deaths were observed at the lower doses (males; 5.5 mg/kg bw: females; 2.5, 5.5 or 10 mg/kg bw).
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No significant differences were seen in body weights, body weight gain or food consumption, except for a body weight gain reducetion in the 4 surviving high dose females at week 1.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- No overt changes in chemistry were seen, with the possible exception of a moderate increase in alkaline phosphatase noted in the male rats in the 50 mglkg group.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- No gross lesions were noted in any of the dead animals at 120 or 250 mg/kg bw dose. Gross lesions were noted in the rats at 50 mg/kg bw and included red lungs (2 rats), urinary bladder calculus (2 rats), red ovaries (2 rats), dark eye (1 rat) and small seminal vesicles (1 rat). Red ovaries were also observed in all surviving rats at the 10 mg/kg bw (10/10) and 4/10 at the 5.5 mg/kg bw dose levels.
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 5.5 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- clinical signs
- gross pathology
- mortality
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 2.5 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- clinical signs
- gross pathology
- mortality
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- In a repeated dose dermal toxicity study in rats, conducted by a method comparative to OECD TG 410, involving dermal application of tetramethylammonium hydroxide for 4 weeks clinical signs of toxicity and adverse histopathological effects were observed. Based on these findings, the NOAELs for repeated dose dermal toxicity were considered to be 5.5 mg/kg bw/day in male rats and 2.5 mg/kg bw/day in female rats.
- Executive summary:
In a repeated dose dermal toxicity study, rats were exposed for 4 weeks (6 hours/day, 5 days/week) to tetramethylammonium hydroxide (TMAH) at doses of 0, 5.5, 50, 120 and 250 mg/kg bw/day in male rats and 0, 2.5, 5.5, 10 and 50 mg/kg bw/day in female rats. In addition to erythema, edema and/or scabbing observed at the application sites in all of the treated animals, red ovaries were observed in female rats at 5.5, 10 and 50 mg/kg bw/day, and red lungs, urinary bladder calculus, dark eye and small seminal vesicles in male and/or female rats at 50 mg/kg bw/day. Based on these findings, the NOAELs for repeated dose dermal toxicity were considered to be 5.5 mg/kg bw/day in male rats and 2.5 mg/kg bw/day in female rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.